The risk of malnutrition and its clinical implications in older patients with cancer

Aim: Malnutrition is a common geriatric syndrome with multiple negative outcomes including mortality. However, there is a scarcity of literature that focuses on the relationship between malnutrition risk and its clinical implications on geriatric syndromes and mortality among cancer patients. The aim of this study is to determine the clinical importance of malnutrition risk in geriatric oncology practice. Method: 180 patients with cancer who were ≥ 65 years were included in the study. All patients were questioned in terms of geriatric syndromes, including polypharmacy, frailty, probable sarcopenia, fall risk, dynapenia, depression, cognitive impairment, insomnia, and excessive daytime sleepiness. Mini Nutritional Assessment scores > 23.5 and 17–23.5 were categorized as well-nourished and malnutrition risk, respectively. Results: Of the 180 patients (mean age 73.0 ± 5.6 years, female: 50%), the prevalence of malnutrition risk was 28.9%. There was no statistically significant difference between the groups in terms of age, gender, education, marital status, body mass index, and comorbidities except for chronic obstructive pulmonary disease (p > 0.05). After adjustment for age, sex, and body mass index; polypharmacy (odds ratio [OR]: 3.17; 95% confidence interval [CI], 1.48–6.81), reduced calf circumference (OR: 3.72; 95% CI, 1.22–11.38), fall risk (OR: 2.72; 95% CI, 1.03–7.23), depression (OR: 6.24; 95% CI, 2.75–14.18), insomnia (OR: 4.89; 95% CI, 2.16–11.05), and frailty (OR: 2.44; 95% CI, 1.75–3.40) were associated with malnutrition risk compared to well-nourished patients (p < 0.05). Median survival in patients with malnutrition risk was 21.3 months (range 14.1–28.4 95% CI) and median survival in patients who were defined as well nourished was not reached (p < 0.001). Conclusion: The risk of malnutrition was associated with a higher risk for all-cause mortality in older patients with cancer, and was associated with many geriatric syndromes, including polypharmacy, fall risk, frailty, insomnia, and depression. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.